Immunoglobulines sous-cutanées versus intraveineuses dans les Polyneuropathies Inflammatoires Démyélinisantes Chroniques : étude de minimisation des coûts, rétrospective de 24 mois (notice n° 690595)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04132cam a2200301 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121210007.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Maillan, Gaelle |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Immunoglobulines sous-cutanées versus intraveineuses dans les Polyneuropathies Inflammatoires Démyélinisantes Chroniques : étude de minimisation des coûts, rétrospective de 24 mois |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2012.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 44 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | De nombreuses études montrent l’intérêt des immunoglobulines (Ig) dans le traitement des polyneuropathies inflammatoires démyélinisantes chroniques (PIDC) et certains auteurs se sont intéressés à leur administration par voie sous cutanée (SC) pour l’intérêt qu’elles peuvent avoir en terme de qualité de vie.L’objectif de ce travail est d’évaluer l’impact économique de la prise en charge de patients atteints de PIDC traités par IgSC par rapport à la stratégie traditionnelle faisant appel aux IgIV. Il compare donc les coûts de la prise en charge d’une PIDC dans le but de savoir quelle thérapeutique représente le coût le moins élevé. Cette étude rétrospective de 24 mois sur 487 séjours de patients atteints de PIDC montre que le coût du séjour des patients traités par IgIV est statistiquement différent de ceux traités par IgSC (pLa dimension économique est devenue aujourd’hui incontournable dans le choix thérapeutique entre deux stratégies jugées équivalentes en terme d’efficacité. Outre le fait d’être moins onéreuses, les IgSC en ambulatoire peuvent offrir aux patients un gain en qualité de vie : autonomie, gain de temps... Le passage à domicile pour les patients qui le souhaitent est incontestablement un facteur de qualité de vie, en ce qu’il limite les impacts sur la vie quotidienne d’un traitement chronique. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Subcutaneous immunoglobulin versus intravenous in chronic inflammatory demyelinating polyneuropathy: 24 months retrospective, medico economic analysisMany studies show the value of immunoglobulin (Ig) in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and some authors are interested in their administration by subcutaneous (SC) way for the interest it may have in terms of quality of life.The objective of this study was to evaluate the economic impact of the management of patients with CIDP treated with SCIg over the traditional approach using IVIg. Then, it compares the caring costs for a CIDP patient in order to know which treatment is the least costly. This retrospective study of 24 months from 487 stays of patients with CIDP shows that the cost of living patients treated with IVIg is statistically different from those treated SCIg (p <0.0001): 13 times more expensive. It also appears that the monthly cost of treatment with IVIg is statistically different from that by SCIg (p <0.0001): 3.5 times higher. All statistical results confirm that SCIg treatment is less expensive than IVIg therapy.The economic dimension has now become essential in the therapeutic choice between two strategies considered equivalent in terms of efficiency. Besides being less costly, outpatient SCIg can offer patients an increased quality of life: independence, saveing time ... The transition to home for patients who wish, is undoubtedly a factor of quality of life, in that it limits the impacts on the daily life of a chronic treatment. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immunoglobuline |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | traitement ambulatoire |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | polyneuropathie inflammatoire démyélinisante chronique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | analyse médico-économique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | immunoglobulin |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | outpatient treatment |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | chronic inflammatory demyelinating polyneuropathy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | medico-economic analysis |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Magy, Laurent |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Javerliat, Madeleine |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ratsimbazafy, Voa |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Journal d'économie médicale | 29 | 8 | 2012-05-01 | p. 387-408 | 0294-0736 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-journal-de-gestion-et-d-economie-medicales1-2011-8-page-387?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-journal-de-gestion-et-d-economie-medicales1-2011-8-page-387?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux